Avid Bioservices Inc (CDMO)

[biopharm]

Avid CDMO IP assets known well by Martin Hynes III works for MAPP and Eli Lilly Research Labs ...ties DTRA / BARDA via Ronald T Aimes ( ex Peregrine and VERY well aware of PS Targeting ) and MRIGlobal did much of the contract work via you guessed it, Rubicon --where Massag Parseghian and Rich Richieri landed after leaving Peregrine and are they aware of PS Targeting ? HELL YES and much more....

I will say this, if there is no competing bid as there was no competing bid back on the shift of the IP assets to Oncologie, then Roche is in on the sandbox game with the rest of them

Well we know now why all the Eli Lilly backed folks at Omeros published the PS Targeting significance back on Sept 10 2019 as it is well known that the blockade of flipped PS is vital for ALL solid tumors and ALL non responders etc etc
_____

Rubicon (directly from there website)

A modified Annexin A5 created in Dr. Reutelingspergerâ??s lab is being adapted by the Rubicon team for targeting of extracellularly-exposed PS in the tumor microenvironment. A direct PS-binder, Annexin A5 holds great promise as an immunotherapeutic agent.

http://www.rubiconbio.com/about/

(Once one sees all the PS Targeting related research Rich Richieri was in the midst of ....and now, Avid the pure play CDMO wants Richieri ? I guess the BOD did not want to be questioned about all this ...but hey, if contracts come in all is fine as they say

______

Now it gets better ...but some IIS now have all this info and more and the bottom line is that is where Eli Lilly folks come into the picture and hell, I can understand dual technology for military and civilian but when John Springs Stafford gets hired on to lie to shareholders it seems...and that is where the line is crossed

Actually the line was crossed with the death of PS Targeting inventor of Bavi etc the late Dr Phil Thorpe

_____

Martin Hynes III

Experience
Mapp Biopharmaceutical
Vice President
Mapp Biopharmaceutical
Oct 2014 - Present 5 years 1 month
San Diego , CA

Six Sigma Champion
Senior Director of Product Research and Development
Six Sigma Champion
Jan 2006 - Present 13 years 10 months
Led deployment of Six Sigma program in Product Research and Development organization of ~1500 employees

Executed over 300 Six Sigma projects that have resulted in significant cost and cycle time reductions

Lead major cross-functional drug development cycle time improvement efforts

Lead a group of 20 black belts selected for their upward potential and leadership ability
Led deployment of Six Sigma program in Product Research and Development organization of ~1500 employees

Executed over 300 Six Sigma projects that have resulted in significant cost and cycle time reductions

Lead major cross-functional drug development cycle time improvement efforts

Lead a group of 20 black belts selected for their upward potential and leadership ability
Lilly Research Laboratories
Senior Director, Six Sigma Champion
Lilly Research Laboratories

Jan 1979 to Present 40 years 10 months
Eli Lilly
Senior Director
Eli Lilly
2009 - Sep 2014 5 years
Senior Director
Product Research and Development
Six Sigma Champion
Senior Director
Product Research and Development
Six Sigma Champion
Eli Lilly
Director of Quality and Operations
Eli Lilly
Feb 2002 -Dec 2005 3 years 11 months
Quality
Led the development of a training, procedures and records management organization that provides a competitive advantage by reducing regulatory risk and meeting FDA Quality System expectations
Developed and delivered annual Quality updates on Good Manufacturing Practices and Good Laboratory Practices regulatory changes
Lead Quality oversight committee
Receipt of Quality Advocate Award
Supervised a staff of approximately 50

Operations
Formed project management group to manage molecule-enabling projects
Developed functional capacity management system, business process and computer system to support development of all molecule and molecule-enabling projects
Supervised a staff of approximately 10
Quality
Led the development of a training, procedures and records management organization that provides a competitive advantage by reducing regulatory risk and meeting FDA Quality System expectations
Developed and delivered annual Quality updates on Good Manufacturing Practices and Good Laboratory Practices regulatory changes
Lead Quality oversight committee
Receipt of Quality Advocate Award
Supervised a staff of approximately 50

Operations
Formed project management group to manage molecule-enabling projects
Developed functional capacity management system, business process and computer system to support development of all molecule and molecule-enabling projects
Supervised a staff of approximately 10
Sh

Lilly Research Laboratories
Director of Global Business Integration Project Implementation
Lilly Research Laboratories
Jun 2000 - Feb 2002 1 year 9 months
Led the implementation of the SAP enterprise system in the global Lilly Research Laboratories organization
Including Human Resources, Financial, Clinical Grants and Project Systems Management functionality

Developed a global communication and change management strategy for Lilly Research Laboratories employees in more than 50 countries

Delivered project on time and within approved scope to over 10,000 global research employees

Largest implementation of SAP Project Systems time entry system ever undertaken
Making Lilly the first major pharmaceutical company to be able to integrate drug development project timelines and costs within an enterprise system

This system is being utilized successfully for both project management and capacity management in Lilly's global research organization

Approximately 25 direct reports

Director of Projects Management
Led the implementation of the SAP enterprise system in the global Lilly Research Laboratories organization
Including Human Resources, Financial, Clinical Grants and Project Systems Management functionality

Developed a global communication and change management strategy for Lilly Research Laboratories employees in more than 50 countries

Delivered project on time and within approved scope to over 10,000 global research employees

Largest implementation of SAP Project Systems time entry system ever undertaken
Making Lilly the first major pharmaceutical company to be able to integrate drug development project timelines and costs within an enterprise system

This system is being utilized successfully for both project management and capacity management in Lilly's global research organization

Approximately 25 direct reports

Director of Projects Management
Sh

Eli Lilly
16 years
Director of Project Management
1994 - 2001 7 years
Director of Project Management for Neuroscience
Director of Project Management for Neuroscience
Director of Projects Management
Jan 1995 - Jan 1997 2 years 1 month
Had line management responsibility for Neuroscience and Endocrine project managers and their associates (approximately 30 people)
Played a key role in the reengineering of Lilly Drug Development Process (Quality Speed Values (QSV))
Developed projects management core competency model with Human Resource component
Utilized in professional titles process, individual development plans, and collection of team feedback
Seen as "one of the most comprehensive and effective competency models in industry today" (Kerzner, 2000, 2003)
Established project management workbench
Led the team to develop a web site for Drug Development Information
Team received the 1999 President's Award for this contribution
Several major companies offered to purchase this tool

Led the development of Milestone reporting
Led the development of the milestone tracking system and database
Central source of all key milestones and project history
Provided monthly status reports to government committees

Updated cross-functional drug development process maps

Led the development of the facilitated planning process for drug development teams that led to improved development plans as evidenced by improved on-time delivery
A radical redesign of our planning process
Seen as "best in class" within the industry
Had line management responsibility for Neuroscience and Endocrine project managers and their associates (approximately 30 people)
Played a key role in the reengineering of Lilly Drug Development Process (Quality Speed Values (QSV))
Developed projects management core competency model with Human Resource component
Utilized in professional titles process, individual development plans, and collection of team feedback
Seen as "one of the most comprehensive and effective competency models in industry today" (Kerzner, 2000, 2003)
Established project management workbench
Led the team to develop a web site for Drug Development Information
Team received the 1999 President's Award for this contribution
Several major companies offered to purchase this tool

Led the development of Milestone reporting
Led the development of the milestone tracking system and database
Central source of all key milestones and project history
Provided monthly status reports to government committees

Updated cross-functional drug development process maps

Led the development of the facilitated planning process for drug development teams that led to improved development plans as evidenced by improved on-time delivery
A radical redesign of our planning process
Seen as "best in class" within the industry
Show less
Director Of Quality Assurance
1990 â?? 19944 years
Director Of Quality Assurance for Research and Development
Director Of Quality Assurance for Research and Development
Director of Clinical Research
Jan 1987 â?? Jan 19903 years 1 month
Director of Clinical Research
1987 â?? 19903 years
Lilly Japan, Kobe Japan
Lilly Japan, Kobe Japan
Director of Clinical Research
Jan 1985 â?? Jan 19872 years 1 month
the Kobe affiliate from 3 to 48 people
Led the newly-formed clinic